Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 184

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

Jones, Paul W., Singh, Dave, Bateman, Eric D., Agusti, Alvar, Lamarca, Rosa, de Miquel, Gonzalo, Segarra, Rosa, Caracta, Cynthia, Garcia Gil, Esther · 2012 · European Respiratory Journal

Abstract

The efficacy and safety of two doses of aclidinium bromide were evaluated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). In this 24-week, double-blind trial, patients were randomised to twice-daily aclidinium (200 μg or 400 μg) or placebo. The primary efficacy end-point was change in trough forced expiratory volume in 1 s (FEV 1) at week 24. Other end-points included peak FEV 1, health status (St George's Respiratory Questionnaire; SGRQ) and dyspnoea (Transitional Dyspnoea Index; TDI). Overall, 828 patients were randomised. At week 24, significant improvements from baseline were observed with aclidinium 200 μg and 400 μg versus placebo for trough FEV 1(99 and 128 mL; both p<0.0001) and peak FEV 1(185 and 209 mL; both p<0.0001). Peak FEV 1 improvements on day 1 were comparable with week 24. Aclidinium 200 μg and 400 μg produced significant improvements over placebo in baseline-adjusted mean SGRQ total score (-3.8 and -4.6 units; p<0.001 and p<0.0001) and TDI focal score (0.6 and 1.0 units; p<0.05 and p<0.001) at week 24. With both aclidinium doses, the incidence of anticholinergic adverse events was low, and similar to placebo. Twice-daily aclidinium significantly improved bronchodilation, health status and dyspnoea, and was well tolerated in patients with COPD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.00225511

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 184

Metadata

Authors
Jones, P. W., Singh, D., Bateman, E. D., Agusti, A., Lamarca, R., de Miquel, G., Segarra, R., Caracta, C., & Garcia Gil, E.
Venue
European Respiratory Journal
Published
2012-03-22
Volume
40
Issue
4
Pages
830-836
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2171697174
Cited by
184
References
1
FWCI
22.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. https://app.cochat.ai/papers/10.1183/09031936.00225511
The paper
Jones, P. W., Singh, D., Bateman, E. D., Agusti, A., Lamarca, R., de Miquel, G., Segarra, R., Caracta, C., & Garcia Gil, E. (2012). Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal. https://doi.org/10.1183/09031936.00225511

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.